Get started
Author

Tongjian Cui

Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial
2022 · Zhihao Lu, Junye Wang, et al. · BMJ · 501
PDF
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)
2022 · Jianming Xu, Yi Li, et al. · Nature Communications · 147
PDF
Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).
2020 · Jianming Xu, Yi Li, et al. · Journal of Clinical Oncology · 26
Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study
2016 · Jianqiu Wu, Yongping Song, et al. · BMC Cancer · 23
PDF
Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China
2018 · Jian-Qiu Wu, Yong-Ping Song, et al. · Chinese Medical Journal · 18
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial
2025 · Aiping Zhou, Pengfei Shen, et al. · The Lancet Oncology · 17
Pivotal single-arm, phase 2 trial of tasurgratinib for patients with fibroblast growth factor receptor (FGFR)-2 gene fusion-positive cholangiocarcinoma (CCA).
2024 · Junji Furuse, Bo Jiang, et al. · Journal of Clinical Oncology · 15
PDF
Effects of sintilimab plus chemotherapy as first-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 study
2024 · Zhihao Lu, Li Kong, et al. · EClinicalMedicine · 13
Tasurgratinib (E7090) for cholangiocarcinoma with fibroblast growth factor receptor 2 fusions/rearrangements: a multicenter, open-label, Phase 2 study
2025 · Lin Shen, Huaxin Duan, et al. · Japanese Journal of Clinical Oncology · 9
PDF
Retrospective analysis of immune-related adverse events of the immune checkpoint inhibitors of PD-1/PD-l1 in the Fujian provincial hospital
2022 · Jianping Zheng, Tongjian Cui, et al. · European Journal of Inflammation · 4
A biomarker-based prediction model for risk of locoregional recurrence in pathologic stage IIIA-N2 non-small cell lung cancer.
2020 · Guicheng Jiang, Junpeng Huang, et al. · Europe PMC (PubMed Central) · 4
Multiomics Integrative Analysis Identifying EPC1 as a Prognostic Biomarker in Head and Neck Squamous Cell Carcinoma
2022 · Yongmei Dai, Wenhan Chen, et al. · BioMed Research International · 3
PDF
Expression and Biological Functions of EPC1 in Nasopharyngeal Carcinoma
2021 · Yongmei Dai, Wenhan Chen, et al. · Archives of Iranian Medicine · 3
PDF
[Study of the correlation between the colorectal cancer Chinese medicine syndrome types and (excision repair cross-complementing 1, ERCC1) gene polymorphisms].
2012 · Tong-Jian Cui, Yi-Qian Chen, et al. · PubMed · 3
Abstract CT075: Updated overall survival outcomes from a randomized, double-blind phase III study of sintilimab versus placebo in combination with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (ORIENT-15)
2023 · Zhihao Lu, Junye Wang, et al. · Cancer Research · 2
Treatment patterns, effectiveness, and safety of Trastuzumab in Chinese patients with metastatic gastric cancer: Interim analysis of the EVIDENCE registry study.
2017 · Shukui Qin, Shen Lin, et al. · Journal of Clinical Oncology · 2
A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer
2022 · Min Yan, Peng Yuan, et al. · Therapeutic Advances in Medical Oncology · 1
Quality of life, effectiveness, and compliance of fruquintinib in the treatment of metastatic colorectal cancer: Results from a prospective real-world study.
2023 · Jun Zhang, Hong-Mei Zhang, et al. · Journal of Clinical Oncology
PDF
Observation on the clinical efficacy and side effects of EGFR-TKI ± chemotherapy in the treatment of EGFR mutation-positive advanced lung adenocarcinoma
2022 · Jianping Zheng, Tongjian Cui, et al. · European Journal of Inflammation
Screening Genes Crucial for Nasopharyngeal Carcinoma Using Weighted Gene Coexpression Network Analysis Combined with Methylation Data Analysis
2020 · Yongmei Dai, Wenhan Chen, et al. · SSRN Electronic Journal
Additional file 1: Table S1. of Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study
2016 · Wu, Jianqiu, Song, Yongping, et al. · Figshare
A Prospective, Observational Study on the Safety and Effectiveness of Rituximab Plus Chemotherapy As the First-Line Treatment of Diffuse Large B-Cell Lymphoma
2014 · Jifeng Feng, Jianqiu Wu, et al. · Blood
[A multicenter study of rituximab-based regimen as first-line treatment in patients with follicular lymphoma].
2014 · Jianqiu Wu, Yongping Song, et al. · PubMed
[Clinical features of rituximab plus chemotherapy as first-line treatment in patients with diffuse large B-cell lymphoma].
2014 · Jifeng Feng, Jianqiu Wu, et al. · PubMed
Treatment of Bone Metastases with Integrative Traditional and Western Medicine
2012 · Tongjian Cui · Health and Research
Works count: 26
Citation count: 791
H-index: 9
I10-index: 8
Year
Topic
Type